v3.26.1
SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Reportable Segments
The Company’s CEO, who is the Company’s Chief Operating Decision Maker, manages the business through three operating segments, consistent with how the Company’s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following operating segments, which also qualify as reportable segments: (i) Vision Care, (ii) Pharmaceuticals and (iii) Surgical. These segments are generally determined based on the decision-making structure of Bausch + Lomb and the grouping of similar products and services.
•The Vision Care segment consists of: (i) sales of contact lenses that span the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses, and (ii) sales of contact lens care products, OTC eye drops that address various conditions, including eye allergies, conjunctivitis, dry eye and redness relief, and eye vitamin and mineral supplements.
•The Pharmaceuticals segment consists of sales of a broad line of proprietary and generic pharmaceutical products for post-operative treatments and the treatment of a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases.
•The Surgical segment consists of sales of medical device equipment, consumables and technologies for the treatment of cataracts, corneal, vitreous and retinal eye conditions, which includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery.
The Company’s Chief Operating Decision Maker uses segment profit to assess operating performance and make resource allocation decisions for each of its segments. Segment profit is based on operating income (loss) after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of Bausch + Lomb’s businesses and incurs certain expenses, gains and losses related to the overall management of Bausch + Lomb, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
Segment Revenues and Profit
Segment revenues and profits for the three months ended March 31, 2026 and 2025 were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended March 31,
(in millions)20262025202620252026202520262025
Revenues
Product Sales$708 $654 $304 $266 $227 $213 $1,239 $1,133 
Other Revenues3 2 1 1 1 1 5 4 
711 656 305 267 228 214 1,244 1,137 
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)271 251 78 93 133 137 
Cost of other revenues— — 1 1 — — 
Selling, general and administrative228 221 138 153 73 73 
Research and development10 8 22 9 13 11 
Segment Profit$202 $176 $66 $11 $9 $(7)277 180 
Corporate(161)(174)
Amortization of intangible assets(57)(67)
Other expense, net(26)(22)
Operating income (loss)33 (83)
Interest income4 3 
Interest expense(97)(94)
Loss on extinguishment of debt(1)— 
Foreign exchange and other (3)(6)
Loss before provision for income taxes$(64)$(180)
Revenues by Segment and by Product Category
Revenues by segment and product category were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended March 31,
(in millions)20262025202620252026202520262025
Pharmaceuticals$1 $1 $265 $221 $— $— $266 $222 
Devices253 235 — — 227 213 480 448 
OTC444 409 — — — — 444 409 
Branded and Other Generics10 9 39 45 — — 49 54 
Other revenues3 2 1 1 1 1 5 4 
$711 $656 $305 $267 $228 $214 $1,244 $1,137 
The top ten products/franchises represented 57% and 54% of total revenues for the three months ended March 31, 2026 and 2025, respectively.